Stockreport

ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF R&D Expenses : R&D expenses increased to $141.8 million in 2023, up from $98.4 million in 2022. Net Loss : GAAP net loss widened to $160.8 million for 2023, or ($3.74 [Read more]